Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 19Gastrointestinal 6Breast 5Thoracic 4Sarcoma 3CNS 3Lymphoid 2Gynecologic 2Plasma cell 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 14Uterine Cervical Neoplasms 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Fallopian Tube Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Peritoneal Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Vulvar Neoplasms 1Urethral Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Penile Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Multiple Myeloma 1

Interventions

pembrolizumab 35Paclitaxel 10Nivolumab 10Carboplatin 9atezolizumab 7Docetaxel 7Cisplatin 7Ipilimumab 5Gemcitabine 5Cyclophosphamide 5spartalizumab 4fludarabine 4Fluorouracil 4lenvatinib 3durvalumab 3cemiplimab 3avelumab 3Vorinostat 3Trastuzumab 3Oxaliplatin 3Leucovorin 3Immunoglobulin G 3Fulvestrant 3Cetuximab 3Bevacizumab 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Capecitabine × Gynecologic × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡